Table 2.
Base-case analysis from the health care sector perspective for the 10-year simulation cost-effectiveness∗
| UC | EXER | CBT | EXER+CBT | |
|---|---|---|---|---|
| Intervention-related cost ($)† | 1,615 | 1,346 | 1,757 | 1,736 |
| Cost of the EXER or CBT intervention | 0 | 320 | 694 | 1,033 |
| Resource use and cost of medical care outside Program ACTIVE II | 1,615 | 1,026 | 1,063 | 704 |
| Outcome cost ($)‡ | 74,411 | 74,368 | 74,865 | 74,693 |
| Total cost ($) | 76,026 | 75,714 | 76,622 | 76,429 |
| QALYs | 4.665 | 5.047 | 4.955 | 5.355 |
| Incremental total cost vs. UC ($) | −313 | 596 | 403 | |
| Incremental QALY vs. UC | 0.382 | 0.290 | 0.690 | |
| ICER vs. UC ($) | Cost saving | 2,058 | 585 |
∗
Cost-effectiveness of the Program ACTIVE II interventions assuming the diminishing intervention effects after the end of the trial.
†
Intervention-related cost refers to the per-participant costs over the 15-month intervention period of Program ACTIVE II and includes the costs of the EXER intervention, CBT intervention, and EXER+CBT intervention and the resource use and cost of medical care outside Program ACTIVE II.
‡
Outcome cost refers to the per-participant medical costs of type 2 diabetes and its complications.